
Heron Therapeutics, Inc.: updates and filings
Price
$0.25
November 20, 2026Market cap $48M
What Ploutos Investor adds for Heron Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 29% since Nov 9, 2026, when the 10-Q these figures come from was filed ($0.37 then, $0.26 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 9, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026SOLICITING MATERIAL PURSUANT TO 240.14A-12FormDFAN14A
- Nov 9, 2026Additional annual meeting materialFormDEFA14A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Additional annual meeting materialFormDEFA14A
- Nov 9, 2026Results of operationsForm8-K
- Nov 9, 2026Material agreement entered, change to shareholders' rights, Regulation FD disclosureForm8-K
- Oct 27, 2026Shares registered for employeesFormS-8
- Sep 29, 2026Material agreement enteredForm8-K
- Aug 14, 2026Material agreement entered, change to shareholders' rightsForm8-K
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operationsForm8-K
- Jun 25, 2026Delisting noticeForm8-K
- Jun 16, 2026Shareholder voteForm8-K
- Jun 2, 2026Other material eventsForm8-K
- May 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 20, 2026Preliminary proxy statementFormPRE 14A
- Apr 6, 2026Officer or director changeForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | DFAN14A | SOLICITING MATERIAL PURSUANT TO 240.14A-12 | Document |
| Nov 9, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Nov 9, 2026 | 8-K | Material agreement entered, change to shareholders' rights, Regulation FD disclosure | Document |
| Oct 27, 2026 | S-8 | Shares registered for employees | Document |
| Sep 29, 2026 | 8-K | Material agreement entered | Document |
| Aug 14, 2026 | 8-K | Material agreement entered, change to shareholders' rights | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Jun 25, 2026 | 8-K | Delisting notice | Document |
| Jun 16, 2026 | 8-K | Shareholder vote | Document |
| Jun 2, 2026 | 8-K | Other material events | Document |
| May 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 20, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 6, 2026 | 8-K | Officer or director change | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Apr 25, 1995: every report, 8-K, meeting and letter. Of its other filings (926 in all), the newest.
The full analysis
What do Heron Therapeutics's filings show?
The filings are where every one of Heron Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.